Italy · Delayed Price · Currency is EUR Svas Biosana Statistics
Total Valuation
Svas Biosana has a market cap or net worth of EUR 47.32 million. The enterprise value is 86.39 million.
| Market Cap | 47.32M |
| Enterprise Value | 86.39M |
Important Dates
The next estimated earnings date is Friday, June 26, 2026.
| Earnings Date | Jun 26, 2026 |
| Ex-Dividend Date | Jun 1, 2026 |
Share Statistics
Svas Biosana has 5.22 million shares outstanding. The number of shares has decreased by -1.74% in one year.
| Current Share Class | 5.22M |
| Shares Outstanding | 5.22M |
| Shares Change (YoY) | -1.74% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.96% |
| Owned by Institutions (%) | 7.04% |
| Float | 1.69M |
Valuation Ratios
The trailing PE ratio is 7.01 and the forward PE ratio is 7.13.
| PE Ratio | 7.01 |
| Forward PE | 7.13 |
| PS Ratio | 0.33 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 17.34 |
| P/OCF Ratio | 7.37 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.91, with an EV/FCF ratio of 31.66.
| EV / Earnings | 12.76 |
| EV / Sales | 0.61 |
| EV / EBITDA | 4.91 |
| EV / EBIT | 7.06 |
| EV / FCF | 31.66 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.82 |
| Quick Ratio | 1.27 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 4.35 |
| Debt / FCF | 28.00 |
| Interest Coverage | 2.96 |
Financial Efficiency
Return on equity (ROE) is 10.38% and return on invested capital (ROIC) is 8.51%.
| Return on Equity (ROE) | 10.38% |
| Return on Assets (ROA) | 4.36% |
| Return on Invested Capital (ROIC) | 8.51% |
| Return on Capital Employed (ROCE) | 11.05% |
| Weighted Average Cost of Capital (WACC) | 6.10% |
| Revenue Per Employee | 406,769 |
| Profits Per Employee | 19,454 |
| Employee Count | 348 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 2.75 |
Taxes
In the past 12 months, Svas Biosana has paid 2.37 million in taxes.
| Income Tax | 2.37M |
| Effective Tax Rate | 25.93% |
Stock Price Statistics
The stock price has increased by +16.11% in the last 52 weeks. The beta is 0.95, so Svas Biosana's price volatility has been similar to the market average.
| Beta (5Y) | 0.95 |
| 52-Week Price Change | +16.11% |
| 50-Day Moving Average | 8.76 |
| 200-Day Moving Average | 8.59 |
| Relative Strength Index (RSI) | 55.61 |
| Average Volume (20 Days) | 1,538 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Svas Biosana had revenue of EUR 141.56 million and earned 6.77 million in profits. Earnings per share was 1.29.
| Revenue | 141.56M |
| Gross Profit | 40.08M |
| Operating Income | 12.24M |
| Pretax Income | 9.14M |
| Net Income | 6.77M |
| EBITDA | 17.58M |
| EBIT | 12.24M |
| Earnings Per Share (EPS) | 1.29 |
Balance Sheet
The company has 37.47 million in cash and 76.41 million in debt, with a net cash position of -38.93 million or -7.45 per share.
| Cash & Cash Equivalents | 37.47M |
| Total Debt | 76.41M |
| Net Cash | -38.93M |
| Net Cash Per Share | -7.45 |
| Equity (Book Value) | 67.53M |
| Book Value Per Share | 12.87 |
| Working Capital | 60.83M |
Cash Flow
In the last 12 months, operating cash flow was 6.42 million and capital expenditures -3.69 million, giving a free cash flow of 2.73 million.
| Operating Cash Flow | 6.42M |
| Capital Expenditures | -3.69M |
| Depreciation & Amortization | 5.34M |
| Net Borrowing | 8.47M |
| Free Cash Flow | 2.73M |
| FCF Per Share | 0.52 |
Margins
Gross margin is 28.32%, with operating and profit margins of 8.64% and 4.78%.
| Gross Margin | 28.32% |
| Operating Margin | 8.64% |
| Pretax Margin | 6.45% |
| Profit Margin | 4.78% |
| EBITDA Margin | 12.42% |
| EBIT Margin | 8.64% |
| FCF Margin | 1.93% |
Dividends & Yields
This stock pays an annual dividend of 0.25, which amounts to a dividend yield of 2.76%.
| Dividend Per Share | 0.25 |
| Dividend Yield | 2.76% |
| Dividend Growth (YoY) | -20.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 19.56% |
| Buyback Yield | 1.74% |
| Shareholder Yield | 4.50% |
| Earnings Yield | 14.31% |
| FCF Yield | 5.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Svas Biosana has an Altman Z-Score of 1.83 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 6 |